Medical Access Program for Patritumab Deruxtecan

Study Number

3950024

Phase

N/A

Age Group

Adult

Principal Investigator

Grace Dy

Purpose

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

Check your eligibility for this trial

Check now

Full Title

Medical Access Program for Patritumab Deruxtecan (HER3-DXd, U3-1402)

ClinicalTrials.Gov ID

NCT06099639

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.